Guoyi Yilian Secures Tens of Millions RMB Series A Funding from Tongrentang-Backed Fund to Build Professional Clinical Prescription Transformation System

In January 2024, Beijing Guoyi Yilian Health Technology Co., Ltd. (hereinafter referred to as “Guoyi Yilian” or the “Company”) recently completed its Series A financing round. The round was led by Beijing Tongrentang Senior Care Investment Management Co., Ltd. The funds raised will be used to advance the improvement and optimization of the Company’s system for translating renowned traditional Chinese medicine (TCM) clinical prescriptions, and to expand the application scenarios of TCM technological achievements in both clinical and out-of-hospital settings.

Tongrentang Heritage and Innovation Capital is a private equity fund management platform under Beijing Tongrentang Group. As a key external investment vehicle for the Group, it primarily focuses on mergers and acquisitions and equity investments in areas spanning the upstream and downstream of Tongrentang Group’s industrial chain, innovative drugs, medical devices, digital healthcare, medical services, and the commercialization of traditional Chinese medicine (TCM) achievements.

Guoyi Yilian is a leading domestic enterprise in innovative technologies for the translation of digital medical achievements. Leveraging partnerships with multiple authoritative research institutions in China, it has assembled over 100 renowned senior Traditional Chinese Medicine (TCM) practitioners and high-level R&D professionals specializing in medical industrial technologies. Through its proprietary achievement translation system, the company has successfully commercialized more than 200 clinical medical achievements and invention patents. Its strategic layout spans prescription circulation, in-hospital preparations, new drug translation, as well as out-of-hospital and consumer healthcare sectors. The translated outcomes primarily include cosmeceuticals, TCM-based conditioning pastes, dietary supplements, healthy food products, daily chemical products, and disinfection/medical device products.

Furthermore, the company has independently developed innovative drug delivery technologies, overcoming domestic bottlenecks in “external therapy of Traditional Chinese Medicine (TCM).” Its related products currently cover 20 provinces and regions across China, and it will establish external therapy centers for nearly 10,000 hospitals nationwide, providing highly precise and convenient technical services for topical formulations. Guoyi Medical Alliance has also made in-depth strategic layouts in areas such as SaaS systems for TCM clinics, herbal decoction centers, and products based on the concept of “medicine and food sharing the same origin.”

Ms. Zhao Xin, Founder, Chairwoman, and CEO of Guoyi Medical Alliance“The company stated: ‘Guoyi Yilian has successfully completed product finalization and commercialization, achieving phased milestones by leveraging its mature system for transforming well-established clinical formulas into marketable products, the core technologies independently developed by its R&D team, and the company’s product and operational capabilities. This round of financing will help us systematically and efficiently advance subsequent R&D iterations and conduct clinical studies on select products. We will continue to increase R&D investment in our core technologies, strive for technological breakthroughs and product iterations, and serve public health through continuous innovation.’”

Dr. Lu Jian, General Manager of the Equity Investment Department at Tongrentang Heritage & Innovation Capital, the Lead Investor“It has been stated that, as a leading domestic enterprise in the transformation of digital medical achievements, Guoyi Yilian has truly achieved integration across the upstream and downstream of the traditional Chinese medicine (TCM) and consumer healthcare industrial chains. Leveraging its advanced technologies and craftsmanship in dosage forms and extraction, along with its self-built clinic SaaS network, decoction center system, distributor system, and MCN channels, Guoyi Yilian has ensured that the ‘treasures’ held by renowned veteran TCM practitioners and scientists have ‘technological carriers, guaranteed efficacy, branded products, established transformation channels, scaled production, and tangible means for inheritance.’ This approach has broken through the industry’s predicaments and chaos in achievement transformation, characterized by ‘apparent but not actual transformation, transformation without commercialization, and commercialization without viable pathways.’ Amidst the booming trend of the TCM big health and consumer healthcare industries, Guoyi Yilian has made special contributions to the development of TCM in non-pharmacological treatments and consumer healthcare, based on its ingenious business model and unique technical processes, demonstrating high industrial, social, and commercial value. As a time-honored TCM brand with a history of nearly 400 years, Tongrentang bears the mission and responsibility of revitalizing the TCM industry, and we are willing to join hands with Guoyi Yilian to truly achieve ‘upholding integrity while pursuing innovation.’”Senior Investment Managers Yang Qingjia and Wang Qing, along with Investment Manager Hu Zhehan, remarked: “In the current environment, Guoyi Yilian’s remarkable business growth and financial performance are rare achievements, which are strongly correlated with the company’s strategic positioning, business model, and the founder’s background and experience. The company’s development stage aligns well with current market trends, making its future prospects promising.”